Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Children and Adolescents With Active Juvenile Psoriatic Arthritis
NCT06869551Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2025
- Primary completion
- Mar 2030
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of deucravacitinib in juvenile psoriatic arthritis (JPsA) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Time to first flare during the withdrawal period at 42 weeks. Started Mar 2025; status: recruiting.
02
Drugs
deucravacitinib
03
Conditions
juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on NCT06869551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06869551.